ORDER NOW! The MyRisk Test is the only germline core panel with 100% of genes strongly recommended by ASCO guidelines.2,3
The MyRisk Test evaluates 63 clinically recommended genes grounded in strong clinical evidence to reveal hereditary cancer risks and treatment-impacting variants across more than 11 cancer types, empowering you to personalize care plans with confidence.
The MyRisk Test focuses exclusively on genes backed by clinical evidence and cited in national oncology guidelines—so every result has the potential to inform care.1-3
of genes strongly recommended by ASCO guidelines are tested to help ensure no relevant findings are missed1-3
of genes tested are cited in national oncology guidelines, helping to avoid the uncertainty associated with non-actionable result1-3
Gene-disease associations and medical management recommendations are updated regularly based on the latest clinical evidence, helping ensure your results are meaningful, actionable, and appropriate for clinical use.
The MyRisk Test provides you with more critical answers for more patients by definitively classifying up to 63% of variants that other labs could not.4
Did you know that up to 10% of germline variants are missed by tumor testing alone?2 The MyRisk Test identifies germline BRCA1/2 variants that may impact use of targeted therapies such as PARP inhibitors.5,6
The MyRisk Test identifies hereditary cancer syndromes associated with a risk for secondary cancers, directly impacting treatment decisions to reduce the occurrence of subsequent cancer.
National guidelines recommend germline testing as part of the workup for patients diagnosed with ovarian, breast, pancreatic, prostate, and colon cancer.1 Additionally, while genomic testing has long been recommended for all patients diagnosed with metastatic or advanced cancers, the American Society of Clinical Oncology (ASCO) now advises multigene germline testing for patients who meet criteria regardless of their tumor results.2
The MyRisk Test is appropriate for patients with a personal and/or family history of certain cancers, including:
*Eligible for MyRisk STAT, except for patients with government insurances, including but not limited to Tricare Prime, Medicaid, Indian Health Services, VA, etc.†
The MyRisk Test analyzes 63 genes linked to more than 11 cancer types.
Every MyRisk Test report includes:
A mutation has been identified.
An elevated risk has been identified.
No clinically significant mutation.
Mutation of uncertain risk has been identified.
The MyRisk Test, combined with Myriad’s industry-leading Variant Classification Program,6 utilizes RNA testing strategically, along with other proprietary tools, to deliver highly accurate variant interpretations, ensuring precise and actionable results for more patients.
Classifies most variants through advanced baseline DNA analysis—without the need for upfront RNA testing 4,6
Industry’s lowest reported VUS rates for BRCA1 and BRCA2 of 0.3% and 0.7%, respectively6
Our Lifetime Classification Commitment sends amended reports whenever a patient’s MyRisk VUS result is reclassified as clinically significant
The MyRisk Test definitively classifies up to 63% of variants other labs could not4
Myriad pioneered the use of RNA analysis in 2015 and offers RNA analysis to all patients with an eligible VUS. When RNA analysis is performed, our methodology allows us to classify variants with precision, at no additional cost ,and often without the need for a re-draw.7,8
The MyRisk Test is available through leading EMR platforms, including Epic and OncoEMR—streamlining ordering and result access within your existing workflow.
Provider completes the test request form (in the EMR system, portal or via paper TRF)
Patient blood or saliva sample is collected and submitted to Myriad Genetics with the test kit
Results are sent to the ordering provider (in the EMR system, portal, or via mail)
There should not be a trade-off between turnaround time and receiving an accurate, comprehensive risk assessment when determining surgical treatment for patients. MyRisk STAT was developed for trusted results without the wait.
MyRisk STAT test results for eligible patients diagnosed with breast, pancreatic or colorectal cancer.†
Results delivered for all other patients
If you already count on the MyRisk Test, you’ll soon have even more reason to choose Myriad.
We’ve brought the Precise Tumor®, MyChoice® CDx Myriad HRD Companion Diagnostic Test, and immunohistochemistry (IHC) testing for PD-L1 and FOLR1/FRa into your OncoEMR workflow, so you can order germline and tumor genomic tests in one seamless process, from a single lab.
For a complete approach to cancer risk management and treatment planning, the MyRisk Germline Test can be combined with tumor genomic testing to deliver powerful results informing patient care across the entire care continuum—from assessing hereditary cancer syndromes to helping guide treatment decisions.
For your patients with advanced cancer, combine germline and tumor genomic insights to identify hereditary cancer risks and actionable mutations, enabling personalized treatment plans and targeted therapies. The MyRisk Test and Precise Tumor Test focus on clinically relevant variations in the genome, using powerful and unique classification tools, including targeted RNA analysis, to deliver accurate variant interpretations.
For your patients with early-stage breast cancer, pair germline testing with tumor genomic insights and breast cancer recurrence assessment to guide personalized decisions on risk-reducing surgeries and adjuvant therapy strategies.
For your patients with ovarian cancer at any stage, integrate germline and tumor genomic insights with tumor homologous recombination deficiency (HRD) testing to inform comprehensive treatment options with PARP inhibitors.
The MyRisk Test delivers treatment-focused reporting with actionable summaries, providing clear insights for surgical and treatment decisions to support more confident patient care.
The MyRisk Test delivers unmatched accuracy, with variant classification techniques independently verified and clinically validated at >99.9% accuracy.5
Transparent pricing with personalized cost estimates, financial assistance, and other affordability options, including direct pay. Learn more
Learn more about our tests or explore ordering options to bring the MyRisk Test to your practice.
Request more information about how Myriad’s Oncology solutions can benefit you/your patients.
By submitting your personal information, you agree to be contacted with newsletters, marketing or promotional materials, and other information that may be of interest to you. You may opt-out of receiving communications from us by following the unsubscribe link or the instructions provided in the communication we send. For further information on our privacy practices and commitment to protecting your privacy, please visit our Privacy Notice.
Contact Information
†Patients with government payers (Medicare, Medicare Advantage, TriCare) are not eligible for MyRisk STAT.
©Myriad Genetics, Myriad Oncology, MyRisk, Precise Tumor, MyChoice, Prolaris, BRACAnalysis CDx, RiskScore, and their respective logos, are either trademarks or registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions. EndoPredict and the EndoPredict logo are either trademarks or registered trademarks of Eurobio Scientific.